Walleye Capital
OKUR

Walleye Capital’s OnKure Therapeutics OKUR Stock Holding History

Walleye Capital’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,495
Closed -$116K – 5305
2024
Q4 		$116K Buy
+13,495
New +$204K ﹤0.01% 4061
2023
Q3 		– Sell
-4,955
Closed -$325K – 5403
2023
Q2 		$325K Buy
+4,955
New +$399K ﹤0.01% 2726

Other funds holding OKUR

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Walleye Capital's OKUR Position: Q1 2025 in Review

Walleye Capital sold out of OnKure Therapeutics (OKUR) in Q1 2025, closing a stake of 13,495 shares — an estimated $116K sold.

Walleye Capital first reported a position in OKUR in Q2 2023 and held it in 2 quarters. The position peaked at $325K in Q2 2023. 47 funds tracked by Wall St. Rank hold OKUR as of Q1 2025.

  • Walleye Capital reported no remaining OnKure Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 13,495 OnKure Therapeutics shares in Q1 2025, an estimated $116K.
  • Walleye Capital first reported a position in OnKure Therapeutics in Q2 2023 and held it in 2 quarters.
  • Walleye Capital's OnKure Therapeutics position peaked at $325K in Q2 2023.
  • 47 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.